DR. PARMINDER SINGH M.D. NPI 1194961763

NPI Details

DR. Parminder Singh, M.D. is a hematology and oncology internal medicine in Scottsdale, AZ with 24 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Parminder Singh, M.D. NPI is 1194961763. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

13400 E SHEA BLVD
SCOTTSDALE, AZ
ZIP 85259-452
Phone: (480) 301-8000

The NPI 1194961763 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, decitabine, 1 mg (HCPCS:J0894)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg (HCPCS:Q5116)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Collection of blood sample from implanted device (HCPCS:36591)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Telephone medical discussion with physician, 21-30 minutes (HCPCS:99443)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Transfusion of blood or blood products (HCPCS:36430)
• Application of on-body injector for under skin injection (HCPCS:96377)

The enumeration date for this NPI number is 1/1/2009 and was last updated on 9/8/2020.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: